المؤلفون: Minnella, Filippo, Urso, Teodoro, Lazarescu, Mihai T., Lavagno, Luciano

مصطلحات موضوعية: Computer Science - Hardware Architecture, Electrical Engineering and Systems Science - Signal Processing

الوصف: Residual neural networks are widely used in computer vision tasks. They enable the construction of deeper and more accurate models by mitigating the vanishing gradient problem. Their main innovation is the residual block which allows the output of one layer to bypass one or more intermediate layers and be added to the output of a later layer. Their complex structure and the buffering required by the residual block make them difficult to implement on resource-constrained platforms. We present a novel design flow for implementing deep learning models for field programmable gate arrays optimized for ResNets, using a strategy to reduce their buffering overhead to obtain a resource-efficient implementation of the residual layer. Our high-level synthesis (HLS)-based flow encompasses a thorough set of design principles and optimization strategies, exploiting in novel ways standard techniques such as temporal reuse and loop merging to efficiently map ResNet models, and potentially other skip connection-based NN architectures, into FPGA. The models are quantized to 8-bit integers for both weights and activations, 16-bit for biases, and 32-bit for accumulations. The experimental results are obtained on the CIFAR-10 dataset using ResNet8 and ResNet20 implemented with Xilinx FPGAs using HLS on the Ultra96-V2 and Kria KV260 boards. Compared to the state-of-the-art on the Kria KV260 board, our ResNet20 implementation achieves 2.88X speedup with 0.5% higher accuracy of 91.3%, while ResNet8 accuracy improves by 2.8% to 88.7%. The throughputs of ResNet8 and ResNet20 are 12971 FPS and 3254 FPS on the Ultra96 board, and 30153 FPS and 7601 FPS on the Kria KV26, respectively. They Pareto-dominate state-of-the-art solutions concerning accuracy, throughput, and energy.

الوصول الحر: http://arxiv.org/abs/2309.15631Test

المؤلفون: Charles Lynch, Ajibayo Adeyeye, El Mehdi Abbara, Ashraf Umar, Mohammed Alhendi, Chris Minnella, Joseph Iannotti, Nancy Stoffel, Mark Poliks, Manos M. Tentzeris

المصدر: Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)

مصطلحات موضوعية: Medicine, Science

الوصف: Abstract With the current development of the 5G infrastructure, there presents a unique opportunity for the deployment of battery-less mmWave reflect-array-based sensors. These fully-passive devices benefit from having a larger detectability than alternative battery-less solutions to create self-monitoring megastructures. The presented ‘smart’ skin sensor uses a Van-Atta array design enabling ubiquitous local strain monitoring for the structural health monitoring of composite materials featuring wide interrogation angles. Proof-of-concept prototypes of these ‘smart’ skin millimeter-wave identification tags, that can be mounted on or embedded within common materials used in wind turbine blades, present a highly-detectable radar cross-section of − 33.75 dBsm and − 35.00 dBsm for mounted and embedded sensors respectively. Both sensors display a minimum resolution of 202 $$\upmu $$ μ -strain even at 40 $$^{\circ }$$ ∘ off-axis enabling interrogation of the fully-passive sensor at oblique angles of incidence. When interrogated from a proof-of-concept reader, the fully-passive, sticker-like mmID enables local strain monitoring of both carbon fiber and glass fiber composite materials. The sensors display a repeatable and recoverable response over 0–3000 $$\upmu $$ μ -strain and a sensitivity of 7.55 kHz/ $$\upmu $$ μ -strain and 7.92 kHz/ $$\upmu $$ μ -strain for mounted and embedded sensors, respectively. Thus, the presented 5G-enabled battery-less sensor presents massive potential for the development of ubiquitous Digital Twinning of composite materials in future smart cities architectures.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/97afb22075c548b1a783a942b8680352Test

المؤلفون: Wei, C., Chen, A., Amidei, D., Anderson, N., Carpenter, E., Cooperrider, L., Dai, T., Diehl, E., Ferretti, C., Li, J., Lugato, P., Minnella, J., Moskaitis, S., Nelson, K., Pillsbury, V., Salzer, E., Simpson, L., Wang, Z. C., Wang, Z. R., Weaverdyck, C., Yang, Z., Zhou, B.

مصطلحات موضوعية: Physics - Instrumentation and Detectors, High Energy Physics - Experiment

الوصف: This paper reports on the design and construction of infrastructure and test stations for small-diameter monitored drift tube (sMDT) assembly and testing at the University of Michigan (UM) to prepare for the ATLAS Muon Spectrometer upgrade for the high-luminosity program of the Large Hadron Collider. Procedures of the tube assembly and quality assurance and control (QA/QC) tests are described in detail. More than 99% of the tubes meet the tube QA/QC specifications based on 2100 tubes built at UM. The UM test stations are also used for QA/QC testing on the tubes constructed at Michigan State University. These tubes are being used to construct the sMDT chambers which will replace the current MDT chambers of the barrel inner station of the Muon Spectrometer.
Comment: 16 pages, 14 figures

الوصول الحر: http://arxiv.org/abs/2209.03864Test

المؤلفون: Paola Sasso, Alfonso Savastano, Faustino Vidal-Aroca, Angelo Maria Minnella, Giuseppe Francione, Leonardo Sammarco, Valentina Cima, Ritangela Ghiraldelli, Roberta Mattei, Stanislao Rizzo

المصدر: Ophthalmology and Therapy, Vol 13, Iss 3, Pp 697-707 (2024)

مصطلحات موضوعية: Late-stage age-related macular degeneration (AMD), Geographic atrophy, Visual impairment, Implantable ophthalmic device, Intraocular lens, Low vision, visual rehabilitation, speed reading, reading acuity, smaller-incision new generation implantable miniature telescope, SING IMT, Ophthalmology, RE1-994

الوصف: Abstract Introduction In this work, our aim is to report the functional outcomes of cataract surgery with smaller-incision new-generation miniature telescope (SING IMT) implantation followed by rehabilitation training in patients with central visual loss due to late-stage age-related macular degeneration (AMD). Methods This retrospective study included patients who were monocularly implanted with SING IMT and then followed a rehabilitation program based on 6 biweekly sessions focused on visual abilities, reading, writing, visual motor integration and mobility. A total of 11 participants were included in this study. Reading acuity (RA), reading speed (RS), and fixation stability (FS) were assessed biweekly at 6-, 8-, 10-, 12-, 14-, and 16-week follow-up visits after SING IMT implantation and at a final assessment at 24 weeks. Best-corrected distance visual acuity (BCDVA) was also measured at baseline and at the same postoperative timepoints. Results Mean baseline BCDVA was 12.5 ± 8.6 letter score. Both RA and RS were found to be significantly improved from the first rehabilitation session (6 weeks after surgery) to the last session (24 weeks after surgery). At the end of the rehabilitation program, mean RA was 0.45 ± 0.19 LogMAR and mean RS was 30.9 ± 17.6 words per minute. Moreover, all patients achieved a FS of 15 s or more after the last rehabilitation session. Most patients (55%) achieved an improvement of 15 letters in BCDVA at the end of the study. Conclusions This study suggests that rehabilitation training can improve visual functions of patients with late-stage AMD implanted with SING IMT in real-world tasks such as reading skills.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2193-8245Test; https://doaj.org/toc/2193-6528Test

الوصول الحر: https://doaj.org/article/091db96fc37c4ccd880d6d394eab5226Test

المؤلفون: Sara Latini, Veronica Venafra, Giorgia Massacci, Valeria Bica, Simone Graziosi, Giusj Monia Pugliese, Marta Iannuccelli, Filippo Frioni, Gessica Minnella, John Donald Marra, Patrizia Chiusolo, Gerardo Pepe, Manuela Helmer Citterich, Dimitros Mougiakakos, Martin Böttcher, Thomas Fischer, Livia Perfetto, Francesca Sacco

المصدر: eLife, Vol 12 (2024)

مصطلحات موضوعية: mouse, acute myeloid leukemia, tyrosine kinase, Boolean model, drug resistance, cancer therapy, Medicine, Science, Biology (General), QH301-705.5

الوصف: Currently, the identification of patient-specific therapies in cancer is mainly informed by personalized genomic analysis. In the setting of acute myeloid leukemia (AML), patient-drug treatment matching fails in a subset of patients harboring atypical internal tandem duplications (ITDs) in the tyrosine kinase domain of the FLT3 gene. To address this unmet medical need, here we develop a systems-based strategy that integrates multiparametric analysis of crucial signaling pathways, and patient-specific genomic and transcriptomic data with a prior knowledge signaling network using a Boolean-based formalism. By this approach, we derive personalized predictive models describing the signaling landscape of AML FLT3-ITD positive cell lines and patients. These models enable us to derive mechanistic insight into drug resistance mechanisms and suggest novel opportunities for combinatorial treatments. Interestingly, our analysis reveals that the JNK kinase pathway plays a crucial role in the tyrosine kinase inhibitor response of FLT3-ITD cells through cell cycle regulation. Finally, our work shows that patient-specific logic models have the potential to inform precision medicine approaches.

وصف الملف: electronic resource

العلاقة: https://elifesciences.org/articles/90532Test; https://doaj.org/toc/2050-084XTest

الوصول الحر: https://doaj.org/article/046f6248d0ed4a4e8ed3337d150c805eTest

المؤلفون: Romano A., Guglielmino V., Bisogni G., Di Paolantonio A., Minnella A. M., Sciarrone M. A., Vitali F., Maceroni M., Sabatelli M., Luigetti M.

المساهمون: Romano, Angela, Guglielmino, Valeria, Bisogni, Paolo Gaetano, Di Paolantonio, Andrea, Truini, A., Minnella, Angelo Maria, Sciarrone, Maria Ausilia, Vitali, Francesca, Maceroni, Martina, Galosi, E., Sabatelli, Mario, Luigetti, Marco

مصطلحات موضوعية: ATTRv-PN, Disease onset biomarkers, Early diagnosis, Hereditary transthyretin amyloidosis, Presymptomatic carriers, Settore MED/26 - NEUROLOGIA

الوصف: Background Hereditary transthyretin (ATTRv) amyloidosis is a heterogeneous, progressive, multisystemic disease with a life-threatening course if left untreated. Given the current availability of effective therapies, close follow-up of presymptomatic TTR mutation carriers is essential to recognize disease onset at the earliest sign. In addition to routine techniques, in recent years several novel tools have been proposed, although a consensus on their use has not been reached yet. In this paper, we aimed to evaluate possible markers of neuropathic disease onset intended to discriminate clinically asymptomatic carriers from early symptomatic patients, thus allowing timely treatment initiation.Methods Thirty-eight presymptomatic carriers were enrolled. Clinical and electrophysiological findings at first evaluation and follow-up were collected. All carriers underwent an extensive clinical and instrumental evaluation according to the standard clinical practice. One or more non-routine investigations, whose use in this field is not yet validated (henceforth "unconventional"), were additionally assessed in a subgroup of individuals.Results Based on the exclusive use of routine investigations, it was possible to define disease onset in 4/38 carriers during the follow-up. Employing additionally one or more "unconventional" tests, abnormal findings, indicative of a possible "conversion" to symptomatic disease, were detected in further 12 cases. More than half of our study cohort showed findings suggestive of small nerve fiber (SF) involvement at either invasive or non-invasive tests.Conclusions A close, multidisciplinary monitoring of presymptomatic TTR mutation carriers is fundamental, and diagnostic workup should include both routine and "unconventional" tests. Assessment of SF involvement is important also in non-endemic countries.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37938457; info:eu-repo/semantics/altIdentifier/wos/WOS:001101881400001; volume:45; issue:4; firstpage:1675; lastpage:1684; numberofpages:10; issueyear:2024; journal:NEUROLOGICAL SCIENCES; https://hdl.handle.net/10807/274987Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85176013072

الإتاحة: https://doi.org/10.1007/s10072-023-07177-xTest
https://hdl.handle.net/10807/274987Test

المؤلفون: Lorenzo Piemonti, Giovanni Landoni, Antonio Voza, Massimo Puoti, Ivan Gentile, Nicola Coppola, Stefano Nava, Alessia Mattei, Franco Marinangeli, Giulia Marchetti, Paolo Bonfanti, Claudio Maria Mastroianni, Matteo Bassetti, Ernesto Crisafulli, Paolo Antonio Grossi, Alberto Zangrillo, Antonio Desai, Marco Merli, Maria Foggia, Marco Carpano, Lorenzo Schiavoni, Antonella D’Arminio Monforte, Luca Bisi, Gianluca Russo, Fabiana Busti, Cristina Rovelli, Elisabetta Perrotta, Giovanni Goisis, Elizabeth M. Gavioli, Sophie Toya, Maria De Pizzol, Flavio Mantelli, Marcello Allegretti, Enrico Maria Minnella

المصدر: Infectious Diseases and Therapy, Vol 12, Iss 10, Pp 2437-2456 (2023)

مصطلحات موضوعية: COVID-19, Interleukin-8 (IL-8), Reparixin, SARS-CoV-2, Infectious and parasitic diseases, RC109-216

الوصف: Abstract Introduction Polymorphonuclear cell influx into the interstitial and bronchoalveolar spaces is a cardinal feature of severe coronavirus disease 2019 (COVID-19), principally mediated by interleukin-8 (IL-8). We sought to determine whether reparixin, a novel IL-8 pathway inhibitor, could reduce disease progression in patients hospitalized with severe COVID-19 pneumonia. Methods In this Phase 3, randomized, double-blind, placebo-controlled, multicenter study, hospitalized adult patients with severe COVID-19 pneumonia were randomized 2:1 to receive oral reparixin 1200 mg three times daily or placebo for up to 21 days or until hospital discharge. The primary endpoint was the proportion of patients alive and free of respiratory failure at Day 28, with key secondary endpoints being the proportion of patients free of respiratory failure at Day 60, incidence of intensive care unit (ICU) admission by Day 28 and time to recovery by Day 28. Results Of 279 patients randomized, 182 received at least one dose of reparixin and 88 received placebo. The proportion of patients alive and free of respiratory failure at Day 28 was similar in the two groups {83.5% versus 80.7%; odds ratio 1.63 [95% confidence interval (CI) 0.75, 3.51]; p = 0.216}. There were no statistically significant differences in the key secondary endpoints, but a numerically higher proportion of patients in the reparixin group were alive and free of respiratory failure at Day 60 (88.7% versus 84.6%; p = 0.195), fewer required ICU admissions by Day 28 (15.8% versus 21.7%; p = 0.168), and a higher proportion recovered by Day 28 compared with placebo (81.6% versus 74.9%; p = 0.167). Fewer patients experienced adverse events with reparixin than placebo (45.6% versus 54.5%), most mild or moderate intensity and not related to study treatment. Conclusions This trial did not meet the primary efficacy endpoints, yet reparixin showed a trend toward limiting disease progression as an add-on therapy in COVID-19 severe pneumonia and was well tolerated. Trial Registration ClinicalTrials.gov: NCT04878055, EudraCT: 2020-005919-51. Graphical Abstract

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2193-8229Test; https://doaj.org/toc/2193-6382Test

الوصول الحر: https://doaj.org/article/c0e902f5e7584fd495de60572d4fe8e3Test

المؤلفون: Latini, Sara, Venafra, Veronica, Massacci, Giorgia, Bica, Valeria, Graziosi, Simone, Pugliese, Giusj Monia, Iannuccelli, Marta, Frioni, Filippo, Minnella, Gessica, Marra, John Donald, Chiusolo, Patrizia, Pepe, Gerardo, Helmer Citterich, Manuela, Mougiakakos, Dimitros, Böttcher, Martin, Fischer, Thomas, Perfetto, Livia, Sacco, Francesca

المساهمون: Fondazione AIRC per la ricerca sul cancro ETS, Italian Minister of University

المصدر: eLife ; volume 12 ; ISSN 2050-084X

الوصف: Currently, the identification of patient-specific therapies in cancer is mainly informed by personalized genomic analysis. In the setting of acute myeloid leukemia (AML), patient-drug treatment matching fails in a subset of patients harboring atypical internal tandem duplications (ITDs) in the tyrosine kinase domain of the FLT3 gene. To address this unmet medical need, here we develop a systems-based strategy that integrates multiparametric analysis of crucial signaling pathways, and patient-specific genomic and transcriptomic data with a prior knowledge signaling network using a Boolean-based formalism. By this approach, we derive personalized predictive models describing the signaling landscape of AML FLT3-ITD positive cell lines and patients. These models enable us to derive mechanistic insight into drug resistance mechanisms and suggest novel opportunities for combinatorial treatments. Interestingly, our analysis reveals that the JNK kinase pathway plays a crucial role in the tyrosine kinase inhibitor response of FLT3-ITD cells through cell cycle regulation. Finally, our work shows that patient-specific logic models have the potential to inform precision medicine approaches.

الإتاحة: https://doi.org/10.7554/elife.90532.3Test
https://cdn.elifesciences.org/articles/90532/elife-90532-v1.pdfTest
https://cdn.elifesciences.org/articles/90532/elife-90532-v1.xmlTest
https://elifesciences.org/articles/90532Test

المؤلفون: Sasso, Paola, Savastano, Alfonso, Vidal-Aroca, Faustino, Minnella, Angelo Maria, Francione, Giuseppe, Sammarco, Leonardo, Cima, Valentina, Ghiraldelli, Ritangela, Mattei, Roberta, Rizzo, Stanislao

المصدر: Ophthalmology and Therapy ; volume 13, issue 3, page 697-707 ; ISSN 2193-8245 2193-6528

مصطلحات موضوعية: Ophthalmology

الإتاحة: https://doi.org/10.1007/s40123-023-00871-1Test

المؤلفون: Sasso, Paola, Savastano, Alfonso, Vidal-Aroca, Faustino, Minnella, Angelo Maria, Francione, Giuseppe, Sammarco, Leonardo, Cima, Valentina, Ghiraldelli, Ritangela, Mattei, Roberta, Rizzo, Stanislao

المصدر: Ophthalmology and Therapy ; volume 13, issue 3, page 709-709 ; ISSN 2193-8245 2193-6528

مصطلحات موضوعية: Ophthalmology

الإتاحة: https://doi.org/10.1007/s40123-024-00890-6Test